[Prevention by vaccination of adult patients with pulmonary diseases].
Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“.
Immunogenicity, vaccine
Lung diseases, chronic
Pulmonary inflammation
Transplantation
Vaccines, combined
Journal
Der Pneumologe
ISSN: 1613-5636
Titre abrégé: Pneumologe (Berl)
Pays: Germany
ID NLM: 101233663
Informations de publication
Date de publication:
2021
2021
Historique:
accepted:
08
06
2021
pubmed:
20
7
2021
medline:
20
7
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations by the Standing Committee on Vaccination include not only the standard vaccinations in adulthood but also the so-called indication vaccinations. These include vaccinations against pneumococci and influenza. Advances include the recent development of new pneumococcal conjugate vaccines containing additional serotypes and the recommendation of a more effective high-dose vaccine against influenza for persons over 60 years old. With the next scheduled booster vaccination against tetanus and diphtheria a combination vaccine with pertussis antigen should be used. For patients with chronic lung disease the herpes zoster vaccine is recommended over the age of 50 years.
Identifiants
pubmed: 34276271
doi: 10.1007/s10405-021-00402-4
pii: 402
pmc: PMC8274260
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Pagination
327-338Informations de copyright
© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021.
Références
Expert Rev Vaccines. 2018 May;17(5):435-443
pubmed: 29715054
Clin Infect Dis. 2021 Sep 15;73(6):949-956
pubmed: 33580245
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Vaccine. 2020 Jan 29;38(5):1129-1136
pubmed: 31761500
PLoS One. 2019 Jan 11;14(1):e0210353
pubmed: 30633778
PLoS One. 2019 Aug 1;14(8):e0220453
pubmed: 31369597
BMC Infect Dis. 2018 May 3;18(1):203
pubmed: 29724175
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin Infect Dis. 2019 May 30;68(12):2117-2119
pubmed: 30462172
Open Forum Infect Dis. 2014 May 27;1(1):ofu024
pubmed: 25734097
Clin Microbiol Infect. 2018 May;24(5):500-504
pubmed: 28830805
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 May;63(5):588-644
pubmed: 32350583
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
N Engl J Med. 2005 Oct 13;353(15):1555-63
pubmed: 16221778
J Infect Dis. 2018 Feb 14;217(5):731-741
pubmed: 29220496
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
Cochrane Database Syst Rev. 2018 Feb 01;2:CD004876
pubmed: 29388197
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Chest. 2019 Jan;155(1):69-78
pubmed: 30616737
J Infect Dis. 2009 Dec 15;200(12):1861-9
pubmed: 19909082
J Clin Virol. 2014 Oct;61(2):181-8
pubmed: 25066886
Pneumologie. 2021 Jan;75(1):19-30
pubmed: 33242887
N Engl J Med. 2015 Mar 19;372(12):1114-25
pubmed: 25785969
Vaccine. 2017 Mar 23;35(13):1692-1697
pubmed: 28245940
JAMA. 2021 Jun 22;325(24):2448-2456
pubmed: 33929487
Vaccine. 2012 Nov 6;30(48):6802-8
pubmed: 23000122
MMW Fortschr Med. 2019 Jul;161(13):56-60
pubmed: 31313172
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Clin Microbiol Rev. 2016 Jul;29(3):449-86
pubmed: 27029594
Clin Infect Dis. 2013 Sep;57(6):820-7
pubmed: 23788243
Infection. 2021 Jun;49(3):533-537
pubmed: 33774804